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Background
The establishment of the Cancer Drugs Fund (CDF),
which removed the necessity for cost-effectiveness as a
criterion for drugs access and expedited access to non-
NICE appraised drugs, has significantly changed pre-
scribing of cancer drugs for terminally ill cancer patients
in the NHS. Neither clinicians nor the public have a
preference for spending money on cancer over other
disease states. The most effective and efficient way to
spend resource within cancer care is hotly debated.
Materials and methods
Audio-recorded, semi-structured interviews with oncology
and palliative care consultants (n=16) took place in the
South West region (March-October 2013). Transcripts
were analyzed iteratively using constant comparison to
identify and understand common themes. Matrices were
developed to explore and compare derived themes and
highlight dissonant views.
Results
The complex dynamic of personal, familial, media and
political influence on palliative chemotherapy decision-
making were described by participants. Decision-making
around palliative chemotherapies was improved by the
CDF according to all oncology participants. The main
benefit of the CDF was thought to be access to treat-
ments not previously available to patients. However, the
improved availability of high cost drugs caused conflict
for clinicians reconciling the apparent benefits for the
patient and the cost for the population. The disadvan-
tages of the CDF included a potential reduction in clini-
cian discretion in chemotherapy decision-making since
the National CDF Cohort List and a delay in advanced
care planning conversations. The appropriateness of
‘weighting’ the value of life more at the end of life (as
defined by NICE) was felt to be artificial by 5/6 palliative
care and 5/10 oncology consultants. The majority of con-
sultants described an uncomfortable compromise
between the importance of that time to some individuals
offset by the lessened quality of life for the majority (13/
16). Professional opinion clashed most over the role of
Multi-Disciplinary Team meetings (MDTs) in accessing
CDF drugs. MDTs were felt to be a cause for delay and ‘a
tick-box’ exercise (oncologists) and a missed opportunity
for patient advocacy (palliative care).
Conclusions
Clinicians indicated that they mostly approved of the
CDF in enabling patient access to new palliative che-
motherapy. However; clinicians sometimes struggled
with judging the balance between potential gains and
losses in length and quality of life for individual patients
and the level of financial cost incurred by the NHS. The
views of patients accessing drugs through the CDF are
currently being sought in order to improve understand-
ing of the impact of the CDF.
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